The SOS Infertility Association in Romania was founded in 2008 by women struggling with infertility and has since implemented numerous projects to support infertile couples and increase awareness of infertility issues. These projects include advocating for national and local IVF funding programs, offering free IVF procedures through their "A Chance for Life" project, publishing educational materials like a magazine and podcast, providing financial grants for IVF, organizing an annual awareness week, traveling exhibitions, support groups, online communities, and participating in numerous media appearances to destigmatize infertility. After over a decade of work, the Association has changed realities for infertility in Romania.
The SOS Infertility Association in Romania was founded in 2008 by women struggling with infertility and has since implemented numerous projects to support infertile couples and increase awareness of infertility issues. These projects include advocating for national and local IVF funding programs, offering free IVF procedures through their "A Chance for Life" project, publishing educational materials like a magazine and podcast, providing financial grants for IVF, organizing an annual awareness week, traveling exhibitions, support groups, online communities, and participating in numerous media appearances to destigmatize infertility. After over a decade of work, the Association has changed realities for infertility in Romania.
The document summarizes a fertility education magazine in Romania called "What do you know about YOUR FERTILITY?". It is a non-profit project run by the SOS Infertilitatea Association. The magazine contains educational articles on fertility topics and testimonials. It aims to provide couples information as they start their conception journey or deal with fertility issues. The magazine has a print run of 5,000 copies and is distributed for free throughout Romania.
This document introduces a new fertility education magazine in Romania published by the non-profit SOS Infertilitatea Association. The magazine aims to provide educational information about fertility to women aged 18-38 and their partners. It will contain articles about fertility topics, testimonials, and interviews in its 60 pages. The magazine will be freely distributed in hospitals, clinics, and doctors' offices to reach its target audience and provide correct information about fertility.
This document discusses ovarian hyperstimulation syndrome (OHSS) based on data from 28 patients in Romania. It finds that most patients were not properly informed of OHSS risks prior to starting fertility treatments. Nearly half of patients reported not receiving adequate support from their clinics after developing OHSS symptoms. As a result, over 30% of patients who did not get pregnant decided to give up on further fertility treatments due to their traumatic OHSS experiences. The document concludes that while preventing OHSS is important, clinics must also ensure patients are well-informed of risks, can recognize symptoms early, and will receive support if OHSS develops.
This very short document is unintelligible as it only contains repeated gibberish text that does not form words or convey any meaning. It provides no information that can be summarized due to the lack of coherent content.
The document summarizes a fertility education magazine in Romania called "What do you know about YOUR FERTILITY?". It is a non-profit project run by the SOS Infertilitatea Association. The magazine contains educational articles on fertility topics and testimonials. It aims to provide couples information as they start their conception journey or deal with fertility issues. The magazine has a print run of 5,000 copies and is distributed for free throughout Romania.
This document introduces a new fertility education magazine in Romania published by the non-profit SOS Infertilitatea Association. The magazine aims to provide educational information about fertility to women aged 18-38 and their partners. It will contain articles about fertility topics, testimonials, and interviews in its 60 pages. The magazine will be freely distributed in hospitals, clinics, and doctors' offices to reach its target audience and provide correct information about fertility.
This document discusses ovarian hyperstimulation syndrome (OHSS) based on data from 28 patients in Romania. It finds that most patients were not properly informed of OHSS risks prior to starting fertility treatments. Nearly half of patients reported not receiving adequate support from their clinics after developing OHSS symptoms. As a result, over 30% of patients who did not get pregnant decided to give up on further fertility treatments due to their traumatic OHSS experiences. The document concludes that while preventing OHSS is important, clinics must also ensure patients are well-informed of risks, can recognize symptoms early, and will receive support if OHSS develops.
This very short document is unintelligible as it only contains repeated gibberish text that does not form words or convey any meaning. It provides no information that can be summarized due to the lack of coherent content.
Brosura „Acesti copii care, altfel, nu ar fi existat”
ICSI France
1. L'ICSI en France en 2009
Quelles données épidémiologiques
et pharmaco-économiques
Jacques de Mouzon, INSERM, Paris
2. Introduction
• Contexte:
• 1978: LOUISE BROWN (R.Edwards, P.Steptoe)
• 1982: AMANDINE (R.Frydman, J.Testart)
• 1990 : ICSI (Palermo, Van Steirteghem,
Devroey)
• 2007 : Total: 3 millions d ’enfants (160 000
France)
Par an : plus de 200 000 enfants dans le
monde
12 000 en France (1,3 % des naissances)
ICSI= près de 60 % en France en 2006
3. Introduction (2)
Plan:
Données générales, France, Europe et Monde
Pratique et résultats de l’ICSI en France
Aspects pharmaco-épidémiologiques
Données
France:
Agence de la Biomédecine 2006
Fivnat 2005
Europe: EIM 2005
Monde: ICMART 2004
11. Pratique de l’ICSI selon les regions
100%
98,8
80%
76,0
60% 64,8
63,3
59,9
GIFT
56,6 IVF
51,7
40% ICSI
20%
0%
Europe Europe Australia North Asia Latin Middle
2005 2004 & NZ America America East
*excludes Israel
12. ICSI - Faible utilisation, Europe 2005
100
90
80
70
60
50
40
30 FIV
20 ICSI
10
0
Ireland orway
Finland N Sweden France
Bulgaria
Denmark
Russia C.I.S.
United Kingdom
The Netherlands
31. Données pharmaco-économiques
en ICSI
.F Fagnani*, S. Gadenne, J. de Mouzon, Cohen-Bacrie M.
*Cemka-Eval, Bourg La Reine, France
32. Patientes et méthodes
Etude médico-économique de type coût-efficacité, dans
la perspective de l’assurance-maladie.
Critère d’efficacité : nombre de grossesses évolutives
obtenues au bout de 4 cycles successifs dans une cohorte
de 1000 femmes débutant un premier cycle de FIV ou
d’ICSI
Répartition FIV/ICSI au premier cycle : 40 % en FIV et 60 % en ICSI,
(selon les dernières estimations de la répartition en France des 2
techniques, ABM)
33. Patientes et méthodes.
Hypothèses de l’étude
Taux de grossesses évolutives après un cycle
observés dans les 2 essais (EISG , MERIT)
ICSI : Menopur® 20,4 %; Gonal-F® 22,0 %
Diminution relative du taux de grossesses évolutives :
pré -définie à 5% par cycle pour les 3 cycles suivants,
Taux d’abandons : estimés à 20 % par cycle,
Passage de FIV en ICSI : en cas d’échec de la FIV, de 20 %
34. Patientes et méthodes.
Coûts
Coûts pris en compte : exclusivement ceux
remboursés par l’assurance maladie
Stimulation (contrôles biologiques et échographie) et autres étapes
du cycle d’AMP
Coûts des inducteurs estimés pour 75 unités:
Menopur® 22,19 € et Gonal-F 30,79 €
Nombres d’unités par cycle selon les 2 essais.
Bénéfices mesurés à la fois en termes de coûts évités et
de grossesses cliniques obtenues.
35. Nombre total de cycles avec 2
cohortes de 1000 couples FIV / ICSI
3000 2645 2590
2284
2500 2154
2000
1500 Menopur
Gonal F
1000
500
0
FIV ICSI
Calculs pour une cohorte 1000 couples, 4 cycles
36. Nombre total de grossesses avec 2
cohortes de 1000 couples FIV / ICSI
534
540
520
500 476
480 464
450 Menopur
460 GonalF
440
420
400
FIV ICSI
Calculs pour une cohorte 1000 couples, 4 cycles
39. Conclusion pharmaco économique
Différence de Taux de grossesses
coût / ponction
Technique en faveur de Menopur GonalF
Menopur
FIV ∆= 2006 € 24,8 % 20,3 %
ICSI ∆= 1484 € 17,0 % 18,4 %
Au total,Hors indication spécifique,
la FIV a un meilleur ratio efficacité
Menopur a un meilleur ratio coût-efficacité
40. Conclusion
L’ICSI augmente régulièrement en France
Mais à un rythme relativement raisonnable
Ses indications bougent assez peu, privilégiant les
infécondités masculines
Ses résultats sont, en France et dans le monde, très
proches de ceux de la FIV
Avec une politique de transfert voisine
Son coût, supérieur, devrait la faire réserver à ses
indications (infertilité masculine et échec de
fécondation)
L’aspect économique doit aussi être analysé et pris
en compte dans les protocoles de stimulation